Sugi Predict

Sugi Predict / Compounds / SCHEMBL7182295

SCHEMBL7182295

SCHEMBL7182295

Cc1cc(C)c(C(=O)[PH](=O)CCCc2ccccc2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.45
▸ NPC1 O15118 5/20 0.45
▸ RAB9A P51151 5/20 0.45
▸ POLB P06746 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ HDAC3 O15379 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC11 Q96DB2 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182701 0.96 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7186598 0.94 NPC1 (0.43) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7178316 0.94 NPC1 (0.43) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7187167 0.94 NPC1 (0.43) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7188874 0.94 NPC1 (0.43) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7189123 0.94 NPC1 (0.43) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7188493 0.91 L3MBTL1 (0.41) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7181127 0.88 GPR52 (0.48) SMN1; SMN2NPC1RAB9APOLBCYP3A4
SCHEMBL7179814 0.88 RXRA (0.41) SMN1; SMN2NPC1RAB9APOLBKDM4E
SCHEMBL7181051 0.86 SMN1; SMN2 (0.38) SMN1; SMN2NPC1RAB9APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885NPC1 772/4885RAB9A 1818/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885NPC1 872/4885RAB9A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.